Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Miaoqin, Hu, Shiman, Li, Yiling, Jiang, Ting Ting, Jin, Hongchuan, Feng, Lifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677403/
https://www.ncbi.nlm.nih.gov/pubmed/33214545
http://dx.doi.org/10.1038/s41392-020-00347-9
_version_ 1783611965589946368
author Chen, Miaoqin
Hu, Shiman
Li, Yiling
Jiang, Ting Ting
Jin, Hongchuan
Feng, Lifeng
author_facet Chen, Miaoqin
Hu, Shiman
Li, Yiling
Jiang, Ting Ting
Jin, Hongchuan
Feng, Lifeng
author_sort Chen, Miaoqin
collection PubMed
description Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.
format Online
Article
Text
id pubmed-7677403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76774032020-11-20 Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies Chen, Miaoqin Hu, Shiman Li, Yiling Jiang, Ting Ting Jin, Hongchuan Feng, Lifeng Signal Transduct Target Ther Review Article Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control. Nature Publishing Group UK 2020-11-20 /pmc/articles/PMC7677403/ /pubmed/33214545 http://dx.doi.org/10.1038/s41392-020-00347-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Chen, Miaoqin
Hu, Shiman
Li, Yiling
Jiang, Ting Ting
Jin, Hongchuan
Feng, Lifeng
Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title_full Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title_fullStr Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title_full_unstemmed Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title_short Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
title_sort targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677403/
https://www.ncbi.nlm.nih.gov/pubmed/33214545
http://dx.doi.org/10.1038/s41392-020-00347-9
work_keys_str_mv AT chenmiaoqin targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies
AT hushiman targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies
AT liyiling targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies
AT jiangtingting targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies
AT jinhongchuan targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies
AT fenglifeng targetingnuclearacidmediatedimmunityincancerimmunecheckpointinhibitortherapies

Ejemplares similares